Immunodetection of Antibodies in Sera from Symptomatic and Asymptomatic Chilean Chagas' Disease Patients with Trypanosoma Cruzi Recombinant Antigens

Lorca, Myriam; Gonzalez, Andrea; Veloso, Cecilia; Reyes, Viviana; Vergara, U

doi:10.4269/ajtmh.1992.46.44

Cited by 21 publications

(16 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The use of target molecules, with a chemically defined structure specific to the parasite as a tool for the identification of important factors involved in the immunopathology of Chagas disease, is also recognized [11,13,14]. Two recombinant antigens with this profile were therefore used in the present study: the cytoplasmatic repetitive antigen (CRA), which is present in the epimastigote and amastigote, and the flagellar repetitive antigen (FRA), which is present in the epimastigote and trypomastigote forms of T. cruzi [15,16].…”

Section: Introductionmentioning

confidence: 99%

Increased levels of IgA antibodies against CRA and FRA recombinant antigens of Trypanosoma cruzi differentiate digestive forms of Chagas disease

et al. 2010

View full text Add to dashboard Cite

Section: Introductionmentioning

confidence: 99%

Increased levels of IgA antibodies against CRA and FRA recombinant antigens of Trypanosoma cruzi differentiate digestive forms of Chagas disease

et al. 2010

View full text Add to dashboard Cite

“…Selected parasite molecules may be useful in studies on the immunopathological mechanisms of Chagas disease [11]. For instance, T. cruzi-specific antigens could be used in assays to discriminate the clinical forms of chronic Chagas disease.…”

mentioning

confidence: 99%

Cytokine Levels in Serious Cardiopathy of Chagas Disease After In Vitro Stimulation with Recombinant Antigens from Trypanosoma cruzi

Lorena

Braz

et al. 2010

Scandinavian Journal of Immunology

View full text Add to dashboard Cite

The clinical manifestations of human Chagas disease are associated with distinct and complex host–parasite interactions that directly involve the host’s immune system. In this study, we analysed the relationship between the production of intracytoplasmic cytokines after in vitro stimulation with the recombinant antigens CRA (cytoplasmatic repetitive antigen) or FRA (flagellar repetitive antigen) from Trypanosoma cruzi and the chronic cardiac or indeterminate clinical forms of Chagas disease. The chagasic patient groups consisted of 39 individuals, selected at the Chagas Disease Unit of the Oswaldo Cruz University Hospital, whom presented either a cardiac form without cardiac dilatation (CARD 1), cardiac form with cardiac dilatation (CARD 2) or indeterminate form (IND). Blood samples were obtained from these patients and cultured in the presence of CRA or FRA. The cytokines produced by lymphocytes and monocytes after antigen stimulation were analysed by flow cytometry. Our results showed that the IFN‐γ and TNF‐α, produced by CD8+ T lymphocytes after in vitro stimulation with CRA, differed among chagasic patients with CARD 1, CARD 2 or IND. We propose that these cytokines could be utilized as immunological markers for clinical cardiac forms of Chagas disease. In a prospective study of patients presenting IND and CARD 1, the assay performed in this paper could serve as a tool to monitor therapeutic interventions, thus improving the patient’s quality of life.

show abstract

“…These included peptides 30, 36, and SAPA (22,23,38). Other recombinant antigens included but were not restricted to 1.1, 1.2, and 1.3 His.…”

Section: Resultsmentioning

confidence: 99%

“…ITC6 incorporated peptides 30, 36, and SAPA, and ITC8.2 further included peptides 1 and Kmp-11. Peptide 1 has been described as being reactive with a large percentage of symptomatic and asymptomatic patients with Chagas' disease (22,23). Kmp-11 is a cytoskeletal associated protein that is a major component of the cell membrane, and a C terminus peptide has been shown to be reactive with Ͼ50% of chagasic sera (33,35).…”

Section: Discussionmentioning

confidence: 99%

Lateral Flow Immunoassay for Diagnosis of Trypanosoma cruzi Infection with High Correlation to the Radioimmunoprecipitation Assay

Houghton

Stevens

Hjerrild

et al. 2009

Clin Vaccine Immunol

Self Cite

View full text Add to dashboard Cite

The incidence of blood donors seropositive for Trypanosoma cruzi in North America has increased with population migration and more rigorous surveillance. The United States, considered nonendemic for T. cruzi, could therefore be at risk to exposure to parasite transmission through blood or organ donations. Current tests show variable reactivity, especially with Central American sera. Here we describe the development of a lateral flow immunoassay for the rapid detection of T. cruzi infection that has a strong correlation to the radioimmunoprecipitation assay (RIPA) "gold standard" in the United States. Such a test could have utility in small blood banks for prescreening donors, as well as in cardiac transplantation evaluation. T. cruzi consensus and/or RIPA-positive sera from Central and South America were evaluated in enzyme immunoassays (EIAs). These included commercial panels from Boston Biomedica, Inc. (BBI) (n ‫؍‬ 14), and HemaBio (n ‫؍‬ 21). Other sources included RIPA-positive sera from the American Red Cross (ARC) (n ‫؍‬ 42), as well as from Chile. Sera were tested with the multiepitope recombinant TcF. All but one of the BBI samples were positive and 7 of 21 HemaBio samples and 6 of 42 ARC samples were low positive or negative. This observation indicated the need for additional antigens. To complement TcF reactivity, we tested the sera with peptides 30, 36, SAPA, and 1.1, 1.2, and 1.3 His fragments of 85-kDa trans-sialidase. We identified a promising combination of the tested antigens and constructed a single recombinant protein, ITC6, that enhanced the relative sensitivity in U.S. blood donor sera compared to that of TcF. The data on its evaluation using RIPA-confirmed positive sera in EIA and lateral flow immunoassay studies are presented, along with an additional recombinant protein, ITC8.2, with two additional sequences for peptide 1 and Kmp-11. The latter, when evaluated in a dipstick assay with consensus positive sera, had a sensitivity of 99.2% and a specificity of 99.1%.

show abstract

Immunodetection of Antibodies in Sera from Symptomatic and Asymptomatic Chilean Chagas' Disease Patients with Trypanosoma Cruzi Recombinant Antigens

Cited by 21 publications

References 0 publications

Increased levels of IgA antibodies against CRA and FRA recombinant antigens of Trypanosoma cruzi differentiate digestive forms of Chagas disease

Increased levels of IgA antibodies against CRA and FRA recombinant antigens of Trypanosoma cruzi differentiate digestive forms of Chagas disease

Cytokine Levels in Serious Cardiopathy of Chagas Disease After In Vitro Stimulation with Recombinant Antigens from Trypanosoma cruzi

Lateral Flow Immunoassay for Diagnosis of Trypanosoma cruzi Infection with High Correlation to the Radioimmunoprecipitation Assay

Contact Info

Product

Resources

About